Evidence map›Paper›PMID 39781540›Full record

ArticleEuropean heart journal open2025

Trends and disparities in cardiovascular disease-related mortality among adults with myeloproliferative neoplasms in USA.

Siddharth Agarwal, Usama Qamar, Muhammad Shahzeb Khan, Taha Al-Juhaishi, Abdul Rafeh Naqash, Avirup Guha, Eric H Yang, Ana Barac, Zain Ul Abideen Asad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Siddharth AgarwalDepartment of Cardiovascular Disease, Mayo Clinic, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0002-5581-5464
Usama QamarDepartment of Medicine, King Edward Medical University, Lahore 54000, Pakistan.
Muhammad Shahzeb KhanDepartment of Cardiovascular Disease, Duke University School of Medicine, Durham, NC 27710, USA.ORCID https://orcid.org/0000-0003-1250-6351
Taha Al-JuhaishiDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 63117, USA.ORCID https://orcid.org/0000-0002-8359-0178
Abdul Rafeh NaqashDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 63117, USA.
Avirup GuhaCardio-Oncology Program, Medical College of Georgia at Augusta University, Augusta, GA 30912, USA.ORCID https://orcid.org/0000-0003-0253-1174
Eric H YangUCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
Ana BaracInova Schar Cancer Institute and Inova Heart and Vascular Institute, Fairfax, VA 22042, USA.ORCID https://orcid.org/0000-0002-9935-8904
Zain Ul Abideen AsadDepartment of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 63117, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: We aimed to perform a retrospective cohort study using the Centers for Disease Control and Prevention's (CDC's) Wide-Ranging Online Data for Epidemiologic Research (WONDER) database to analyse the trends in cardiovascular disease (CVD)-related mortality in patients with myeloproliferative neoplasms (MPNs) from 1999 to 2020. Methods and results: We analysed the death certificate data from the CDC WONDER database from 1999 to 2020 for CVD with co-morbid myeloproliferative disorders in the US population. Age-adjusted mortality rates (AAMRs) and 95% confidence intervals (CIs) were computed per 1 million population by standardizing crude mortality rates to the 2000 US census population. To assess annual national mortality trends, we employed the Joinpoint regression model, calculating the annual per cent change in AAMR and corresponding 95% CIs. A total of 15 269 deaths related to CVD occurred in patients with co-morbid MPNs from 1999 to 2020. Overall, there was a decreasing trend in CVD-related AAMRs throughout these years. Males contributed to 51% of total deaths, and their AAMR was persistently higher than women throughout the study. Non-Hispanic (NH) Whites had the highest overall AAMR, followed by NH Blacks, NH American Indians or Alaska Natives, Hispanics or Latinos, and NH Asian or Pacific Islanders. Conclusion: Our findings indicate a significant decline with notable gender, racial/ethnic, and regional differences in CVD-related mortality among patients with MPN over the past two decades. We emphasize the importance of a collaborative approach between oncologists and cardiologists in managing these patients, highlighting the potential benefits of integrating cardio-oncology services to enhance patient outcomes.

Indexed as

Cardiovascular diseaseDisparitiesIschaemic heart diseaseMortalityMyeloproliferative neoplasmsOutcome

Identifiers

PMID39781540
PMCPMC11707680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.